Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: ~digs who wrote (2317)	3/14/2008 3:33:52 PM
From: Jibacoa	Respond to of 3722

DIAX still hasn't closed its Feb 12 UG. The 4thQ revenues were up significantly & the loss was also cut substantially. bigcharts.marketwatch.com On Feb 28 WYE announced that it recently received FDA market approval for XYNTHATM, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis. XYNTHA's peptide ligand is part of Dyax’s proprietary phage display library.The drug is now the only recombinant factor VIII treatment to utilize an entirely synthetic purification process. Feb 12 was when it announced that it had granted SNY an exclusive worldwide license for the development and commercialization of its human monoclonal antibody DX-2240, as well as a nonexclusive license to DYAX’s antibody phage display technology. The 4thQ revenues increased to $18.2M vs.$3.2M in 2006 was apparently due primarily to the $15M in revenues from a license agreement with MPSYY in November 2007. The stock is trading around 8.2xBV it has significant LTD, a negative CF around $0.90 & the short ratio is around 7x its ADV The "analysts" have a target around $7.50. If the stock can close above the resistance at $4.80 & with some good news & better market environment, it seems it could retest its Apr H at $6.95 bigcharts.marketwatch.com Bernard